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What is the Alzheimer’s Disease Neuroimaging
Initiative and who funds it?
The Alzheimer’s Disease Neuroimaging Initiative
(ADNI) is a large, highly collaborative longitudinal
cohort study aiming to elucidate biomarker trajectories
in Alzheimer’s disease (AD). ADNI was initially funded
in 2004, based on the urgent need to understand poten-
tial biomarkers better in order to facilitate drug develop-
ment, and the large cost and effort required to conduct
appropriate studies. About two thirds of its budget is
provided by the US National Institute on Aging (NIA),
and about one third comes from pharmaceutical compa-
nies; private foundations have also contributed.
Who participates in the initiative?
ADNI is led by Dr. Michael Weiner at UCSF. The core
operations of the program reside at UCSD, UCLA,
UCDavis, UC Berkeley, U Penn and the Mayo Clinic. In
addition, there are more than 50 performance sites
across the US and Canada.
ADNI investigators study structural and molecular
imaging, blood and cerebrospinal fluid markers, and
genetic markers in cohorts of older individuals followed
longitudinally over years. The cohorts include cogni-
tively normal individuals, as well as those with mild
amnestic cognitive impairment and mild AD. Just over
800 individuals enrolled in the original ADNI cohorts;
all received structural magnetic resonance imaging
(MRI), cognitive, clinical and blood analyses; over half
underwent lumbar punctures, and subgroups were stu-
died by fluorodeoxyglucose positron emission tomogra-
phy (FDG-PET) and amyloid PET imaging.
What were the major achievements of the
initiative in the first five years?
ADNI has been enormously successful, generating more
than 200 scientific publications. Among its achievements
are the standardization of imaging and biochemical
biomarker methodologies, characterization of these bio-
markers cross-sectionally and longitudinally across the
cohorts, demonstration of the relationships among these
diverse measures, and interpretation of its wealth of
data in terms of biomarker models of AD.
ADNI methods and data are utilized by virtually all
academic and commercial AD drug development
research worldwide. ADNI has been launched in Japan,
and aspects of ADNI are reflected in biomarker studies
throughout Europe, Asia and Australia. The data have
contributed substantially to recent revisions of diagnos-
tic criteria for AD and mild cognitive impairment
(MCI).
Have these achievements been translated to the
clinic?
While the impact of ADNI on the AD research commu-
nity is inarguable, its aims are not directly related to
clinical practice. The impact o fA D N Io nt h ec l i n i cw i l l
be realized when its methods succeed in accelerating the
development of effective disease-modifying treatments,
the overarching aim of ADNI.
Is funding a problem in the current climate?
We are fortunate that ADNI has been extended for a
new five year period. ADNI-2, which recently started,
has a funding structure quite similar to the original
ADNI-1, with two thirds from NIA, and most of the
rest from industry contributions. The ADNI team is
greatly appreciative of this financial support despite the
current economic pressures.
What are the aims for ADNI-2?
ADNI-2 continues and extends the original aims of
ADNI. The original cognitively normal and MCI cohorts
continue to be followed, so that we can more fully eluci-
date the entire sequence of events from normal aging
through dementia. A new, very mildly impaired group,
called early MCI, has been defined and is being enrolled,
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any medium, provided the original work is properly cited.along with additional individuals for each of the original
cohorts; recent funding supports the enrollment of a
total of 700 additional participants. Structural MRI,
FDG-PET, amyloid PET, lumbar punctures, genetic ana-
lysis and blood studies, along with cognitive, behavioral
and clinical assessments, are obtained on all participants.
New amyloid PET and structural and functional MRI
methods are now being employed. All data continue to
be shared publicly as they are collected.
How has ADNI contributed to your research?
My work, primarily through the Alzheimer’sD i s e a s e
Cooperative Study ((ADCS), another large consortium
supported by NIA) aims to develop more effective treat-
ments for AD. The ADCS conducts randomized con-
trolled therapeutic trials. Our trial designs and methods
utilize lessons from ADNI extensively.
We believe that the best path to effective disease-mod-
ifying treatment is to move our therapeutic interven-
tions to the earliest possible stage of disease, perhaps
even to the asymptomatic stage. ADNI data have pro-
vided the means of identifying individuals at such early
stages and revealed outcome measures that will allow us
to assess treatment effects in the absence of clinical
symptoms. The value of ADNI data to our work cannot
be overstated.
What are the ways in which the experience
gained by ADNI might be used by other areas?
Two aspects of ADNI deserve the attention of the
wider scientific community: extensive collaboration and
open data sharing. Much has been written about the
conflicting aims of profit-driven pharmaceutical com-
panies, academic investigators, regulatory bodies and
patients and families. ADNI has demonstrated, beyond
question, that the aims of these groups overlap, and
that cooperation is enormously fruitful. All participate
in the design and management of ADNI. And, cru-
cially, all ADNI data are immediately shared openly
with interested individuals worldwide; data are posted
to the web daily, and shared at no cost to virtually all
who request it. Dozens of ADNI papers come from
investigators with no affiliation to the study. All com-
panies, regardless of whether they contribute finan-
cially, have full access to the data.
The ADNI model of extensive collaboration and pub-
lic data sharing should, and I think will, spread to and
benefit other areas of science and medicine.
Do you have any comments for patients or carers
of AD patients?
The major message from ADNI to the community of
patients and families affected by AD is one of increased
hope. ADNI continues to substantially improve the odds
that we will soon have much more effective treatments
for this disease.
Where can I find out more?
Alzheimer’s Disease Neuroimaging Initiative,
http://www.adni-info.org
Alzheimer’s Disease Cooperative Study, http://adcs.org
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